# Incorporating a new criteria of resectability for pancreatic ductal adenocarcinoma

## TL;DR

This paper introduces a new system for determining if pancreatic cancer can be surgically removed, combining anatomy, biology, and patient conditions to improve treatment decisions.

## Contribution

The ABC system integrates biological and conditional factors with anatomy to better guide surgery or neoadjuvant therapy in pancreatic cancer.

## Key findings

- The ABC system improves preoperative assessment and treatment decisions for pancreatic cancer.
- Elevated CA 19–9 levels predict poor outcomes even in anatomically resectable tumors.
- The MetroPancreas model helps predict the futility of surgery and supports personalized treatment choices.

## Abstract

The classification of resectability in pancreatic ductal adenocarcinoma has evolved from purely anatomic criteria to include biological and conditional factors, improving patient selection for surgeryThe ABC (Anatomic, Biological, Conditional) system proposed by the International Association of Pancreatology refines preoperative assessment and guides the decision between initial resection or neoadjuvant therapy.Elevated serum CA 19–9 levels above 500 U/mL, even in anatomically resectable tumors, are associated with worse survival and may indicate the need for neoadjuvant chemotherapy.he MetroPancreas model, based on tumor size and CA 19–9 levels, is a useful tool for predicting the futility of pancreatectomy and supporting individualized clinical decision-making.

The classification of resectability in pancreatic ductal adenocarcinoma has evolved from purely anatomic criteria to include biological and conditional factors, improving patient selection for surgery

The ABC (Anatomic, Biological, Conditional) system proposed by the International Association of Pancreatology refines preoperative assessment and guides the decision between initial resection or neoadjuvant therapy.

Elevated serum CA 19–9 levels above 500 U/mL, even in anatomically resectable tumors, are associated with worse survival and may indicate the need for neoadjuvant chemotherapy.

he MetroPancreas model, based on tumor size and CA 19–9 levels, is a useful tool for predicting the futility of pancreatectomy and supporting individualized clinical decision-making.

Locally advanced pancreatic ductal adenocarcinoma is typically considered unresectable due to major vascular involvement. In recent years, the treatment paradigm for borderline resectable and locally advanced has shifted significantly, with neoadjuvant therapy emerging as the standard of care. This approach, often preferred over upfront surgery, aims to downstage the tumor, reduce the risk of positive margins, and increase the probability of a successful resection and survival.

Anatomical, biological, and conditional factors should be incorporated into clinical practice for the preoperative staging of patients with pancreatic ductal adenocarcinoma. These factors are essential for deciding whether to perform upfront resection or neoadjuvant chemotherapy and optimize outcomes.

The classification of resectability for pancreatic ductal adenocarcinoma is crucial in guiding treatment strategies. A recent system including anatomic (A), biological (B), and conditional (C) factors has been used to select the patients who underwent pancreatoduodenectomy, and centralization has been associated with low mortality and defined as a critical determinant of surgical outcomes. A comprehensive literature review assessed the impact of incorporating the ABC criteria in patients with pancreatic ductal adenocarcinoma. Incorporating biological and conditional criteria for patients with pancreatic ductal adenocarcinoma could enhance patient stratification accuracy and improve clinical outcomes and survival.